Article
Infectious Diseases
Romain Palich, Clotilde Allavena, Gilles Peytavin, Cathia Soulie, Roland Tubiana, Laurence Weiss, Ana Montoya Ferrer, Claudine Duvivier, Olivier Bouchaud, Julie Bottero, Aurore Durand, Minh-Patrick Le, Anne-Genevieve Marcelin, Yasmine Dudoit, Lambert Assoumou, Christine Katlama
Summary: The study aimed to evaluate the efficacy of switching patients from a twice-daily to a once-daily regimen of etravirine/raltegravir in maintaining viral suppression. The results showed a low rate of virological failure and a high treatment success rate at 48 weeks post-switch.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Elsa Nyamankolly, Pantxika Bellecave, Linda Wittkop, Fabien Le Marec, Pierre Duffau, Estibaliz Lazaro, Marc-Olivier Vareil, Camille Tumiotto, Mojgan Hessamfar, Charles Cazanave, Adelaide Perrier, Olivier Leleux, Fabrice Bonnet, Didier Neau
Summary: The efficacy of the TRIO regimen in treatment-experienced HIV-1 patients was evaluated in this study. The proportion of patients experiencing virological failure at Week 24 was described, and baseline plasma viral load and genotypic susceptibility score were found to be associated with virological failure.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Immunology
Anchalee Avihingsanon, Michael D. Hughes, Robert Salata, Catherine Godfrey, Caitlyn McCarthy, Peter Mugyenyi, Evelyn Hogg, Robert Gross, Sandra W. Cardoso, Aggrey Bukuru, Mumbi Makanga, Sharlaa Badal-aesen, Vidya Mave, Beatrice Wangari Ndege, Sandy Nerette Fontain, Wadzanai Samaneka, Rode Secours, Marije Van Schalkwyk, Rosie Mngqibisa, Lerato Mohapi, Javier Valencia, Patcharaphan Sugandhavesa, Esmelda Montalban, Cornelius Munyanga, Maganizo Chagomerana, Breno R. Santos, Nagalingeswaran Kumarasamy, Cecilia Kanyama, Robert T. Schooley, John W. Mellors, Carole L. Wallis, Ann C. Collier, Beatriz Grinsztejn
Summary: In this study, third-line regimens comprising of RAL, DRV/r and/or ETR showed excellent tolerability and high rates of durable virologic suppression among PLWH in LMICs who were failing on second-line PI-based ART.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
(2022)
Article
Infectious Diseases
Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh
Summary: The study showed that D/C/F/TAF was effective in both treatment-naive and treatment-experienced, virologically-suppressed adults, with high virologic response rates and low virologic failure rates. The drug also demonstrated bone/renal safety benefits and a low risk of resistance development, regardless of demographic or clinical characteristics.
HIV RESEARCH & CLINICAL PRACTICE
(2021)
Article
Gastroenterology & Hepatology
Maud Lemoine, Lambert Assoumou, Pierre-Marie Girard, Marc Antoine Valantin, Christine Katlama, Stephane De Wit, Pauline Campa, Hayette Rougier, Jean-Luc Meynard, Coca Necsoi, Anja D. Huefner, Jan Van Luzen, Julian Schulze Zur Wiesch, Jean-Philippe Bastard, Soraya Fellahi, Stefan Mauss, Metodi V. Stankov, Axel Baumgarten, Gerrit Post, Lawrence Serfaty, Vlad Ratziu, Yves Menu, Jerome Schlue, Pierre Bedossa, Jacqueline Capeau, Dominique Costagliola, Georg Behrens, Patrick Ingiliz
Summary: This study aimed to assess the prevalence and associated factors of liver steatosis and advanced fibrosis (AF) in HIV-monoinfected patients at risk of NAFLD. The results showed that two-thirds of the HIV-monoinfected patients with NAFLD had liver steatosis, and around 10% had advanced fibrosis. The CAP technique was accurate for screening steatosis in this population.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Immunology
Clotilde Allavena, Hubert Blain, Xian Abulizi, Laurence Slama, Christine Katlama, Pierre Delobel, Vanessa Rio, Carole Cagnot, Mariem Raho-Moussa, Alain Makinson, Laurence Meyer
Summary: This study aimed to assess the prevalence and risk factors of frailty in people aged 70 years or older with HIV who were on antiretroviral treatment. The results showed a low prevalence of frailty (13.5%) and a high prevalence of prefrailty (63.3%) in this population. Age, low socioeconomic status, and multimorbidities were associated with frailty. These findings highlight the importance of targeting these factors to promote successful aging in older individuals with HIV.
Article
Immunology
Laura Waters, Lambert Assoumou, Ana Gonzalez-Cordon, Stefano Rusconi, Pere Domingo, Mark Gompels, Stephane de Wit, Francois Raffi, Christoph Stephan, Mar Masia, Jurgen Rockstroh, Christine Katlama, Georg M. N. Behrens, Graeme Moyle, Margaret Johnson, Julie Fox, Hans-Jurgen Stellbrink, Giovanni Guaraldi, Eric Florence, Stefan Esser, Jose M. Gatell, Anton Pozniak, Esteban Martinez
Summary: In the NEAT022 trial, virologically suppressed HIV patients at high cardiovascular risk switching from protease inhibitors to dolutegravir showed noninferior virological suppression and significant reductions in lipid and cardiovascular disease risk, regardless of immediate or delayed switching.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Romain Palich, Rachid Agher, Dimoke J. Wetshikoy, Lise Cuzin, Sophie Seang, Cathia Soulie, Roland Tubiana, Marc-Antoine Valantin, Luminita Schneider, Valerie Pourcher, Anne-Genevieve Marcelin, Lambert Assoumou, Christine Katlama
Summary: This study aims to explore the differences in antiretroviral therapy (ART) prescriptions between naive and virally suppressed HIV patients born in France and Sub-Saharan Africa. The findings suggest that the differences in ART prescriptions between these two groups cannot solely be explained by different clinical and virologic situations.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
(2023)
Review
Pharmacology & Pharmacy
Vida Terzic, Lea Levoyer, Melanie Figarella, Elisabetta Bigagli, Noemie Mercier, Lucie De Gastines, Severine Gibowski, Marius Troseid, Jacques Demotes, Inge Christoffer Olsen, Maya Hites, Florence Ader, Jose Ramon Arribas Lopez, France Mentre, Helene Esperou, Dominique Costagliola, John-Arne Rottingen, Julien Poissy, Jean-Christophe Roze, Adilia Warris, Jackie O'Leary, Ricardo M. Fernandes, Lambert Assoumou, Regis Hankard, Mark A. Turner, Yazdan Yazdanpanah, Alpha Diallo
Summary: To ensure the safety of participants and regulatory compliance in academic trials, a centralized pharmacovigilance system was established, allowing sponsors to delegate work. This system consisted of key procedures, a local safety officer network, and centralized safety activities. Lessons learned from four trials demonstrated the ability to manage diverse European requirements and communicate effectively with trial teams.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Immunology
Maria Choufany, Laurence Weiss, Alain Makinson, Helene Roul, Jean-Michel Livrozet, Valerie Pourcher, Giovanna Melica, Christophe Rioux, Jean-Paul Viard, Esaie Marshall, Sophie Grabar, Dominique Costagliola
Summary: The study aimed to assess the risk of CD4 T-cell count decline and its association with severe morbid conditions or death in people with HIV infection. The results showed that CD4 decline was rare but associated with a higher risk of severe morbid conditions or death within the first 6 months.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Adolfo de Salazar, Laura Vinuela, Ana Fuentes, Elisa Teyssou, Charlotte Charpentier, Sidonie Lambert-Niclot, Esther Serrano-Conde, Marta Pingarilho, Lavinia Fabeni, Anne De Monte, Karl Stefic, Carlo Federico Perno, Antonio Aguilera, Iker Falces, Rafael Delgado, Sandra Fernandes, Isabel Diogo, Perpetua Gomes, Dimitrios Paraskevis, Maria-Mercedes Santoro, Francesca Ceccherini-Silberstein, Anne-Genevieve Marcelin, Federico Garcia
Summary: The prevalence of transmitted drug resistance to INSTIs and NRTIs and clinically relevant resistance was evaluated in newly diagnosed HIV patients naive to ART in Europe. The results showed low prevalence rates of INSTI-SDRMs (0.30%), NRTI-SDRMs (5.77%), INSTI-CRR (2.33%), and first-line NRTI-CRR (1.74-2.29%) during 2018-2021.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Guillaume Martin-Blondel, Anne-Genevieve Marcelin, Cathia Soulie, Sofia Kaisaridi, Clovis Lusivika-Nzinga, Karen Zafilaza, Celine Dorival, Laura Nailler, Anais Boston, Anne-Marie Ronchetti, Clea Melenotte, Andre Cabie, Christophe Choquet, Albert Trinh-Duc, Karine Lacombe, Geraldine Gaube, Francois Coustilleres, Valerie Pourcher, Jean-Philippe Martellosio, Nathan Peiffer-Smadja, Marie Chauveau, Pierre Housset, Lionel Piroth, Mathilde Devaux, Gilles Pialoux, Aurelie Martin, Vincent Dubee, Jerome Frey, Audrey Le Bot, Charles Cazanave, Philippe Petua, Roland Liblau, Fabrice Carrat, Youri Yordanov
Summary: This study compared the clinical and virological outcomes in Omicron BA.1 and BA.2-infected patients who received sotrovimab and nirmatrelvir for the prevention of severe COVID-19. The results showed that early administration of nirmatrelvir was associated with faster viral clearance compared to sotrovimab, which may contribute to reducing transmission and preventing viral resistance.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Chemistry, Medicinal
Peter J. Slavish, Maxime G. Cuypers, Mary Ashley Rimmer, Alireza Abdolvahabi, Trushar Jeevan, Gyanendra Kumar, Jamie A. Jarusiewicz, Sivaraja Vaithiyalingam, Jeremy C. Jones, John J. Bowling, Jeanine E. Price, Rebecca M. DuBois, Jaeki Min, Richard J. Webby, Zoran Rankovic, Stephen W. White
Summary: Influenza is a major cause of disease-related deaths globally. Strategies to inhibit influenza virus replication have resulted in the emergence of resistant strains. Baloxavir marboxil, a recently approved compound, is significantly less effective due to a mutation in the active site of the target enzyme. Raltegravir, an HIV inhibitor, shows moderate activity against the enzyme. In this study, researchers used structure-guided approaches to design molecules that effectively target the enzyme's active site and successfully developed potent inhibitors for both wild-type and baloxavir-resistant forms.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Editorial Material
Immunology
Dominique Costagliola
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Lise Cuzin, Philippe Flandre, Clotilde Allavena, Romain Palich, Claudine Duvivier, Agathe Becker, Helene Laroche, Pascal Pugliese, Andre Cabie, Dat'AIDS Study Grp
Summary: This study analyzed the occurrence of virological failure (VF) in patients starting ART with an integrase strand transfer inhibitor (INSTI)-based regimen in recent years and its relationship with previous episodes of low-level viral load (LLVL). The results showed that LLVL was associated with VF, and even in the absence of subsequent failure, LLV episodes have a cost. Therefore, any viral load value above 50 copies/mL should lead to enhanced adherence counseling.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Daniele Armenia, Maria M. Santoro, Charlotte Charpentier, Ada Bertoli, Federica Forbici, Vincent Calvez, Diane Descamps, Francesca Ceccherini-Silberstein, Anne-Genevieve Marcelin, Philippe Flandre
Summary: This study aimed to evaluate integrase resistance and its predictors in HIV-1 infected individuals who failed a dolutegravir-based antiretroviral therapy. Major resistance mutations and genotypic susceptibility score were analyzed. The results showed that INSTI resistance was low and mainly related to previous first-generation INSTI exposure. Monitoring integrase resistance is crucial to preserve the efficacy of INSTI class in the future.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Letter
Infectious Diseases
Aude Jary, Sokleaph Cheng, Stephane Marot, Gervillien Arnold Malonga, Theophile Cocherie, Steve Wignall, Vincent Calvez, Sophat Phal, Kem Vichet, Anne-Genevieve Marcelin, Gauthier Delvallez
JOURNAL OF INFECTION
(2023)
Article
Virology
Djeneba B. Fofana, Houdou Diarra, Ibrahima Guindo, Mahamadou K. Savadogo, Marceline d'Almeida, Fatoumata I. Diallo, Aliou Balde, Cathia Soulie, Amadou Kone, Anne-Genevieve Marcelin, Almoustapha I. Maiga, Sidonie Lambert-Niclot, Mamoudou Maiga, Sally McFall, Claudia A. Hawkins, Robert L. Murphy, Mariam Sylla, Christine Katlama, Jane L. Holl, Vincent Calvez, Laurence Morand-Joubert
Summary: Limited data exist on INI resistance in children living with HIV/AIDS in West Africa. A study was conducted on HIV-1-infected children in Benin and Mali, and it was found that no major INI resistance mutations were detected in INI-naive patients.
Review
Critical Care Medicine
Alain Amstutz, Benjamin Speich, France Mentre, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Charles Burdet, Srinivas Murthy, Lori Elizabeth Dodd, Yeming Wang, Kari A. O. Tikkinen, Florence Ader, Maya Hites, Maude Bouscambert, Mary Anne Trabaud, Mike Fralick, Todd C. Lee, Ruxandra Pinto, Andreas Barratt-Due, Fridtjof Lund-Johansen, Fredrik Mueller, Olli P. O. Nevalainen, Bin Cao, Tyler Bonnett, Alexandra Griessbach, Ala Taji Heravi, Christof Schonenberger, Perrine Janiaud, Laura Werlen, Soheila Aghlmandi, Stefan Schandelmaier, Yazdan Yazdanpanah, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel
Summary: This systematic review and meta-analysis assessed the benefits and harms of remdesivir compared to placebo or usual care in COVID-19 patients hospitalized. The study found that remdesivir reduced mortality in patients who required no or conventional oxygen support but did not have enough evidence for patients on ventilators.
LANCET RESPIRATORY MEDICINE
(2023)